Blink Charging Co Share Price (BLNK.US)

$2.98...-3.44...(-53.58%)

Took a gamble topping up at $3

Joseph Schwartz (5 stars ) of Leerink Partners has outperform and $4 today .

.....................................................................................................................................................................

BIVI Looks more risky sold more of that at profit today .

Persistent Going Concern Risks: Despite recent capital raises, the company continues to face significant financial instability. Financial reports highlight ongoing risks to its ability to continue as a going concern, exacerbated by a total net loss of over $16.4 million for the nine months ending March 2026 and high operational costs for clinical programs.

Bearish Technical Momentum: BioVie has been in a sustained downtrend since April 2026, trading near the bottom of its 52-week range. The stock remains below its 200-day simple moving average, and it has been categorized in a high-volatility "red zone" for financial health for over 30 months.

Regulatory and Litigation Uncertainty: The company faces operational risks stemming from ongoing legal proceedings and the inherent uncertainty of FDA approval processes. Development of its liver disease candidate, BIV201, has notably been delayed pending further partnership funding, illustrating the impact of capital constraints on its strategic timeline.

$3.085...-3.33...(-51.94%)

Fulcrum Therapeutics plummeted following the discontinuation of its lead clinical asset, pociredir. This sudden shift was triggered by FDA safety concerns regarding malignancy risks. Sentiment suggests a highly cautious next quarter as analysts project significantly lower valuations while the company explores strategic alternatives and initiates aggressive cost-cutting measures to preserve its cash reserves.

...................................................................................................................................................................................................

Severe Analyst Downgrades: Major financial institutions significantly lowered their price targets on June 2, 2026, following the pipeline collapse. Piper Sandler slashed its target from $23 to $3, and Stifel dropped its target from $25 to $3, reflecting a total loss of confidence in previous valuation models based on the sickle cell program.

..................................................................................................................................................................................................

Workforce Reductions and Restructuring: In response to the development halt, Fulcrum announced significant restructuring, including a reduction in headcount and operating expenses. Such aggressive cost-cutting typically signals a period of internal instability and a transition toward a shell-like status until a strategic transaction is finalized.

..........................................................................................................................................................................

Bullish view

Substantial Cash Position and Runway: Despite the clinical setback, the company maintains a robust balance sheet with approximately $333.3 million in cash and marketable securities as of March 31, 2026. Management projects this capital provides a runway extending into 2029, offering a safety net for future strategic pivots or potential acquisitions.

Active Search for Strategic Alternatives: Fulcrum has launched a comprehensive review to maximize shareholder value, exploring options such as mergers, acquisitions, or business combinations. This strategic shift could potentially unlock value through a reverse merger or the acquisition of new clinical-stage assets to replace the discontinued pociredir program.

$8.61...-0.06...(-0.69%)

Toped up at $8.3

Not sure what happened to the Filing

https://www.google.com/finance/beta/quote/KYTX:NASDAQ

Kyverna Therapeutics remains steady in May 2026 despite technical indicators suggesting a potential trend shift. Positive Q1 2026 earnings and strong Phase 2 trial data for KYV-101 act as primary catalysts. Analysts project significant upside, though sentiment suggests caution regarding near-term technical volatility and long-term regulatory approvals.

6 analysts $30.00....248.43% Upside

https://www.marketbeat.com/stocks/NASDAQ/KYTX/

Closed $3.945..+0.17...(+4.64%)

Sold out $4.15

6pm ..$ 4.095+0.32(+8.62%)

Back up today above sell target .

https://www.google.com/finance/beta/quote/AIRJ:NASDAQ

AirJoule Technologies declined approximately 5% over the past month. Recent movement was driven by a significant Q1 2026 net loss due to a non-cash impairment charge. However, analysts project a transformational year as the company transitions to commercial deployment, with revenue expected to begin by late 2026.

.....................................................................................................

18/5/26 dropped back to $3.52

................................................................................................

Break-Even Price..$ 3.105

P/L..£ +49.53

Unrealised P/L..£ +154.57

Total P/L..£ +340.79